Clinical characteristics and outcomes of subjects who received FMT or vancomycin for Clostridium difficile infections
| Subject | Sex | Age | Smoking | Severe/moderate | Duration of follow-up (weeks) | Outcome (till last follow-up) |
|---|---|---|---|---|---|---|
| FMT1 | M | 80 | Ex-smoker | Moderate | 16 | Cured |
| FMT2 | M | 52 | No | Severe | 27 | Cured |
| FMT3 | M | 38 | No | Moderate | 17 | Cured |
| FMT4 | F | 76 | No | Moderate | 18 | Cured |
| FMT5 | M | 63 | No | Severe | 18 | Cured |
| FMT6 | M | 88 | No | Severe | 23 | Cured |
| FMT7 | M | 45 | Ex-smoker | Severe | 20 | Recurrence at week 19 |
| FMT8 | F | 89 | No | Moderate | 11 | Recurrence at week 5 |
| FMT9 | F | 38 | No | Severe | 28 | Recurrence at week 28 |
| STD1 | M | 88 | Ex-smoker | Severe | 20 | Recurrence at week 12 |
| STD2 | M | 93 | No | Moderate | 7 | Recurrence at week 7 |
| STD3 | F | 78 | Smoker | Severe | 14 | Cured |
| STD4 | F | 83 | No | Severe | 17 | Cured |
| STD5 | F | 99 | No | Moderate | 26 | Cured |
FMT, faecal microbiota transplantation; STD, standard therapy (vancomycin).